MINIREVIEW: Perspectives on plasmid‐based gene therapy: challenges for the product and the process | Zendy

Kelly William J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

MINIREVIEW: Perspectives on plasmid‐based gene therapy: challenges for the product and the process

Author(s) -

Kelly William J.

Publication year - 2003

Publication title -

biotechnology and applied biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.468

H-Index - 70

eISSN - 1470-8744

pISSN - 0885-4513

DOI - 10.1042/ba20030033

Subject(s) - genetic enhancement , plasmid , clinical trial , computational biology , gene , product (mathematics) , biology , bioinformatics , medicine , genetics , geometry , mathematics

Clinical trials for gene-therapy products began in the 1990s. Currently, most of the 630 completed or on-going trials are in Phase I and II. Because of the safety issues surrounding the use of viral vectors, approx. 25% of the ongoing clinical trials use DNA plasmids to carry the corrective gene (http://www.wiley.co.uk/genmed). The purpose of this perspective (and this issue) is to highlight some of the unique technical challenges and potential solutions associated with the manufacture and expression of a plasmid-based gene-therapy product.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research